China Accelerates Brain-Computer Interface Commercialization with State Backing

China’s brain-computer interface (BCI) sector is transitioning rapidly from research to commercial scale, supported by a new national roadmap and dedicated government funding. In August 2025, seven agencies outlined targets for major technical milestones by 2027 and a complete supply chain by 2030 to build globally competitive firms. To support development, authorities announced an 11.6 billion yuan ($165 million) brain science fund in December 2025. Provinces including Sichuan and Zhejiang have already established medical service pricing to speed insurance integration. Recent capital moves include StairMed Technology raising $48 million in Series B funding and neurotech firm BrainCo filing for a Hong Kong IPO. The market is projected to exceed 120 billion yuan by 2040. Startups like NeuroXess and Gestala are leveraging China’s clinical resources and manufacturing infrastructure to rival US counterparts such as Neuralink, focusing on both invasive implants and non-invasive technologies for healthcare and human augmentation.